Table 1 Baseline characteristics of the children with confirmed COVID-19 (n = 144)
Subject characteristics | Total (number %) |
|---|---|
Age | |
≤ 5 years | 67 (58.7) |
5–18 years | 47 (41.2) |
Long hospitalization | |
≥ 10 days | 72 (63.1) |
< 10 days | 42 (36.8) |
Ward | |
Intensive | 9 (7.8) |
Non-intensive | 105 (92.1) |
The presence of pneumonia | |
Yes | 68 (59.6) |
No | 46 (40.4) |
Comorbid | |
Hematological malignancy | 31 (27.1) |
Neurological disorders | 12 (10.5) |
Kidney disease | 10 (8.7) |
Heart disease | 10 (8.7) |
Gastrohepatological disease | 8 (7.0) |
Lung disease | 5 (4.3) |
Immunodeficiency disorders | 4 (3.5) |
Endocrine disorders | 2 (1.7) |
History of supplementary oxygen | |
Without supplementary oxygen | 38 (33.3) |
Nasal cannula | 66 (57.8) |
Non-rebreathing mask | 4 (3.5) |
Non-invasive ventilator | 1 (0.8) |
Mechanical ventilator | 5 (4.3) |
Severity of COVID-19 | |
Severe-critical | 75 (65.7) |
Mild-moderate | 39 (34.2) |
Nutritional status | |
Obese | 7 (6.1) |
Moderate malnulrition | 24 (21) |
Severe malnutrition | 23 (20.1) |
Good nutrition | 60 (52.6) |
Neutrophil lymphocyte ratio value | |
≥ 5.94 | 20 (17.5) |
< 5.94 | 93 (81.5) |
Antiviral therapy | 65 (57) |
Enoxaparin therapy | 4 (3.5) |
Tocilizumab therapy | 4 (3.5) |
Immunoglobulin therapy | 3 (2.6) |
Adherence to therapy guideline | |
Yes | 103 (90.3) |
No | 11 (9.7) |
Died within 6 months after discharge | 34 (23.6%) |